Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Green Cross Corporation is actively prosecuting a portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently faces 3 pending office actions, which are distributed across the USPTO. These actions are being managed by 3 distinct examiners, indicating that each pending matter is being handled by a different individual. Among these, HAGHIGHATIAN, MINA is identified as the busiest examiner, responsible for 1 pending office action.
The technical scope of the portfolio spans 2 distinct art units, suggesting a broader examination focus than a concentrated portfolio. Despite having 3 pending office actions, the workload is spread across the 3 distinct examiners, with no examiner handling more than 1 pending office action. This distribution may lead to varied prosecution experiences depending on the specific 2 distinct art units assigned to the cases. The presence of 2 distinct art units implies that the matters are being reviewed within different administrative groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.1% | +39.3% |
| DAHLIN, HEATHER RAQUEL | 1 | 41.1% | +47.5% |
| XU, QING | 1 | 50.9% | +55.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559466 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | DAHLIN, HEATHER RAQUEL | 2d overdue |
| 18864068 | NOVEL LIQUID FORMULATION FOR PLASMA PROTEIN | HAGHIGHATIAN, MINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559466 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | DAHLIN, HEATHER RAQUEL | 2d overdue |
| 18864068 | NOVEL LIQUID FORMULATION FOR PLASMA PROTEIN | HAGHIGHATIAN, MINA | — |
| 17059875 | METHOD AND COMPOSITION FOR TREATING HUNTER SYNDROME THROUGH CEREBRAL LATERAL VENTRICLE ADMINISTRATION | XU, QING | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18864068 | NOVEL LIQUID FORMULATION FOR PLASMA PROTEIN | HAGHIGHATIAN, MINA | — | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18559466 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | DAHLIN, HEATHER RAQUEL | 1629 | §102§112 | Final Rejection | 2d overdue | Pending | Nov 07, 2023 |
| 17059875 | METHOD AND COMPOSITION FOR TREATING HUNTER SYNDROME THROUGH CEREBRAL LATERAL VENTRICLE ADMINISTRATION | XU, QING | 1656 | §103Other | Final Rejection | — | Pending | Nov 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial